On the stock market since 2019, it operates in the world of health and science. It has 2,348 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 3% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 74% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $1.5B a year; the problem isn’t sales — it’s costs running above that number.
There is $937.0M in the vault; even if every debt were paid off, $637.1M would remain.
It pays out $0.09 per share each year — regular cash for whoever holds the stock.
A loss of $235.7M against $1.5B in annual sales.
This stock swings about 2 times as much as the market average. Big rallies — and big drops — can both happen fast.
Over the last 12 months, executives reported 61 sells against just 13 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, SY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SY has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.